History lessons - FDA BE 90% CI [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-02-26 00:44 (966 d 10:03 ago) – Posting: # 19974
Views: 4,976

Γεια σου, λακωνικό Οδυσσέα!

» 75/25, 90%CI was rocket science :-D

Don’t forget #3 and #4 mentioned in this post.

The 75/75 rule was proposed in 1978 for tricyclic antidepressants.1

(2) The test drug product shall be deemed to meet the bioequivalence requirement for in vivo testing in humans if the following conditions are met:
(ii) In at least 75 percent of the subjects administered the drug, the test drug product has a bioavailability of greater than 75 percent relative to that of the administered reference material utilizing each subject as his own comparison;

It was defended by the FDA2 but immediately criticized3 because already earlier4,5 it was shown to reject >50% of studies if the variability is large even for T/R=1.

The 80/20 rule (aka the “power approach”) was introduced by the FDA after a workshop in December 1971 (‼).6 Schuirmann showed why it is crap.7 Unfortunately (for historic reasons) it is still part of Phoenix/WinNonlin’s output and happily reported by some (see my rant, follow-up).

@John: The 90% CI was recommended in 1992.8

  1. Fed. Reg. 6913 (Feb. 17, 1978); §320.107:6968–9. [image] free resource.
  2. Cabana BE. Assessment of 75/75 Rule: FDA Viewpoint. J Pharm Sci. 1983;72(1):98–99. doi:10.1002/jps.2600720127.
  3. Haynes JD. FDA 75/75 Rule: A Response. J Pharm Sci. 1983;72(1):99–100. doi:10.1002/jps.2600720128.
  4. Haynes JD. Statistical Simulation Study of New Proposed Uniformity Requirement for Bioequivalency Studies. J Pharm Sci. 1981;70(6):673–5. doi:10.1002/jps.2600700625.
  5. Metzler CM, Huang DC. 1983. Statistical methods for bioavailability and bioequivalence. Clin Res Pract Drug Reg Aff. 1983;1:109–132.
  6. Skelly JP. A History of Biopharmaceutics in the Food and Drug Administration 1968–1993. AAPS J. 2010;12(1):44–50. doi:10.1208/s12248-009-9154-8. [image] Free Full text.
  7. Schuirmann DJ. A comparison of the Two One-Sided Tests Procedure and the Power Approach for Assessing the Equivalence of Average Bioavailability. J Pharmacokin Biopharm. 1987;15(6):657–80. doi:10.1007/BF01068419.
  8. FDA/CDER. Guidance for Industry. Statistical Procedures for Bioequivalence Studies Using a Standard Two-Treatment Crossover Design. Jul 1992. [image] Internet Archive.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,739 posts in 4,546 threads, 1,543 registered users;
online 3 (0 registered, 3 guests [including 3 identified bots]).
Forum time: Tuesday 11:47 CEST (Europe/Vienna)

Sometimes the key to an answer is found
in the way you formulate the question.    David Brin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz